Yoshiyuki Tsujihata

Summary

Affiliation: Pharmaceutical Research Division
Country: Japan

Publications

  1. doi request reprint TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats
    Yoshiyuki Tsujihata
    Metabolic Disease Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan
    J Pharmacol Exp Ther 339:228-37. 2011
  2. doi request reprint Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:3960-74. 2012
  3. doi request reprint Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:1538-52. 2012
  4. doi request reprint The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets
    Hiroaki Yashiro
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Pharmacol Exp Ther 340:483-9. 2012
  5. doi request reprint Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists
    Shinobu Sasaki
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 54:1365-78. 2011

Collaborators

Detail Information

Publications5

  1. doi request reprint TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats
    Yoshiyuki Tsujihata
    Metabolic Disease Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Osaka, Japan
    J Pharmacol Exp Ther 339:228-37. 2011
    ..TAK-875 enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia with a low risk of hypoglycemia and no evidence of β cell toxicity...
  2. doi request reprint Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:3960-74. 2012
    ..Compound 16 (TAK-875) is being evaluated in human clinical trials for the treatment of type 2 diabetes...
  3. doi request reprint Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists
    Nobuyuki Negoro
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26 1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 251 8555, Japan
    J Med Chem 55:1538-52. 2012
    ....
  4. doi request reprint The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets
    Hiroaki Yashiro
    Metabolic Disease Drug Discovery Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Pharmacol Exp Ther 340:483-9. 2012
    ....
  5. doi request reprint Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists
    Shinobu Sasaki
    Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 17 85 Jusohonmachi 2 Chome, Yodogawa ku, Osaka 532 8686, Japan
    J Med Chem 54:1365-78. 2011
    ..These pharmacological results suggest that GPR40 agonists might be novel glucose-dependent insulin secretagogues with little or no risk of hypoglycemia...